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An emcient expression system was constructed for C-EGF, a fusion protein made of a fmgment of the cell-binding domain of human Rbronectin 
(FN) bound with epidcrmal growth factor (EGF), C-EGF was produced in Esch~riclrirr cofi HBIOI cells carrying the recombinant plasmid pCEl02 
as inclusion bodies, which were solubilized and refolded after purification. C-EGF had both cell-adhesive and EGF activities. so it might be more 
effective than EGF in therapeutic applications. This fusion system would be lscful for the construction of a recombinant drug delivery system for 
cells that have libronectin receptors (integrins). 
Fibronectin: Epidermal growth factor; Fusion protein; Recombinant plasmid; Drug delivery system 
1 m INTRODUCTION 
Fibronectins (FN) are multifunctional cell-adhesive 
glycoproteins present in plasma and the extracellular 
matrix. FN contains everal functional domains, includ- 
ing the cell-binding domain, which contributes to the 
cell-adhesive function of FN. The tetrapeptide Arg-Gly- 
Asp-Ser (RGDS) has been identified as a recognition 
signal for cell adhesion [l]. The strength of cell-adhesive 
activity is related to the number of type III homology 
repeats within the cell-binding domain, and the effect of 
contribution by the repeats is inversely related to their 
distance from the RGDS sequence [2]. Based on these 
findings, we have constructed an efficient system for the 
expression in Escitericl~ia coli of a 30.kDa fragment of 
the cell-binding domain of FN, and used the system to 
express a fusion protein of the cell-binding domain and 
the heparin-binding domain of FN [3]. Fusion proteins 
of the cell-binding domain and biologically active pep- 
tides such as growth factors, lymphokines, neuro- 
peptides, or hormones could be useful as a drug delivery 
system (DDS) for target cells that have FN receptors 
(integrins). 
more useful in therapeutic applications than unfused 
EGF. E, coii HBlOl cells carrying the plasmid over- 
produced the fusion protein as inclusion bodies, which 
were solubilized and refolded in active form. This ex- 
pression system allows the efficient expression of un- 
stable smaller polypeptides as fusion proteins and will 
be useful for the construction of a DDS, particularly for 
growth factors. 
2. MATERIALS AND METHODS 
Here, we constructed an expression plasmid for a 
fusion protein of the cell-binding domain of human FN 
and epidermal growth factor (EGF), which might be 
Abhviurions: FN, fibronectin; EGF, epidermal growth factor; DDS, 
drug delivery system; SDS-PAGE, SDS-polyacrylamide g l elcctro- 
phoresis. 
Four synthetic DNAs (EGF-I, -2. -3, and -4) were designed and 
synthesized to construct he human EGF gene with an DNA synthe- 
sizer (Applied Biosystems Inc., Foster, CA). EGF-I (sense strand, 
84.mer) and EGF-2 (antisense strand, 56.mer), which together cor- 
respond to the N-terminal-half of EGF. were annealed (1.5 yg each) 
after phosphorylation of the 5’.terminus of EGF-2. In a similar way, 
EGFJ (sense strand, 8%mer) and EGF4 (antisense strand, 86.mer), 
which together correspond to the C-terminal half of EGF, were 
annealed. The two resultant double-stranded DNAs were mixed and 
ligated in 80 ~1 of solution with 450 units of T4 DNA ligase at 16% 
for 30 min. The resultant 172.bp fragment was isolated by agarose gel 
clectrophoresis. giving the EGF gene with compatible nds; 1.0 yg of 
this was then phosphorylated und ligated with I .O pg of a expression 
vector, pUCl l8NT [3], previously digested with AM and EcoRl. A 
recombinant plasmid, pUC118NT-EGF, that gave a 172.bp NC& 
EcoRl fragment was isolated from E. co/i cells transformed with the 
ligation products. The nucleotide sequence of the EGF gene was 
confirmed by the dideoxy chain termination method [4]. A 1.07.kb 
NC&.%/I fragment was isolated from pUCl ISNT-EGF and inserted 
into the lycol-WI site ofpTF7S20 [2], which expresses thecell-binding 
domain of human FN, giving a plasmid, pCE102. 
2.2. Prorrirt purijcution und refokiing 
Cur~sporrde~~e uddwss: F. Kimizuka, Biopraducts Development E. coli HBIOI cells carrying pCEIO2 were grown in L broth supple- 
Center, Takara Shuzo Co., Ltd., Sunaikc 2257, Noji, Kusauu, Shiga mented with SO y@nl ampicillin as described elsewhere [2]. The cell 
525, Japan. Fax: (81) (775) 65 6965. pellet obtained from a 2.liter culture was suspended inSO ml of buffer 
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A (50 mM Tris-HCI. pH 8.0, 25% sucrose, and 1 mM EDTA) and 
incubated with 4 mg of lysozymc at 4°C for 30 min followed by 
sonication. To the disrupted cell suspension, I50 yl of I .O M MpC12 
and 7,500 units of DNasc 1 were added and the mixture was incubated 
at 37°C for 30 min, After the addition of 10 ml of buffer B (20 mM 
Tris-HCI, pH 7.5,0.2 M NaCI, I .O% deoxycholatc, and 1.0% NP-40) 
~hc insoluble material was isolated as inclusion bodies by centrifuga- 
lion. The inclusion bodies were washed first with buffer C (50 mM 
Tris-HCI, pH 8.0, IO mM EDTA, 100 mM NaCI, and 0.5% Triton 
X-100), secondly with 20% ethylene glycol. and finally with 2.0% 
NP-40. The resultant inclusion body (450 mg as wet weight) was 
dissolved in 25 ml of buffer D (20 mM Tris-HCI, pH 8.0, 250 mM 
DTT. and G M urea). and pm on a column of DEAE-Toyoparl 650-S 
(15 ml) equilibrated with 20 mM Tris-I-ICI (pH 8,O) containing IO mM 
DIT. After the column was washed with the same buffer, C-EGF was 
eluted with a stepwise increase in NaCl concentrations. Two mono- 
clonttl antibodies, FN12-8 [5] and anti-EGF (Wakunaga. Osaka, 
Japan), were used for the detection of the fusion protein by immu- 
noblotting. Pure fractions by SDS-PAGE were pooled and dialyzed 
for 40 h at 4°C against 20 mM Tris-HCI (pH 7.5) containing I .O mM 
reduced glutathione and 0.1 mM oxidized glutathione. The refolded 
protein thus obtained was then dialyzed against phosphate-buffered 
saline (PBS) and lyophilired. 
Synthetic DNA 
Ned 
pUC118~ 
I 
I h-EGF gene NcLWECCA~ 
( pUC118NT-EGF ) 
Fig. I. Scheme for the construction of the expression plasmid. A 
synthetic human EGF gene with cloning sites at both ends was con- 
structcd from four synthetic oligonucleotides and subcloned into 
pUCl li3N with a transcription terminator (/ppT), giving pUCl ISNT- 
EGF. This was digested with NC&Sal1 and the resultant I.ci7-kb 
fragment was inserted into the NC&SO/I site of pTF7520, giving 
pCEIO2, which expresses C-EGF under the control of the fuc pro- 
moter (/f&O). 
2.3. Assay of EGF urtivif~ 
EGF activity was assayed essentially as described by Cohen and 
Carpenter [6]. Briefly, cultured NRK-49F cells were diluted to 5 x 
lO”/ml with DMEM supplemented with 10% FCS and put into a 
96.well microtiter plate (200~1 per well). After incubation of the plate 
at 37°C for 3 days, 40 yl of a PBS solution of the sample was added 
to each well. After incubation of the plate for 18 h longer, 20 ~1 of 
[“Hlthymidinc (0,l PCi) was added to each well and the plate was 
incubated for 6 h. The plate was washed twice with PBS and then 
incubated with 100~1 per well ofO.196 ttypsin for 2 h. The trypsinizcd 
cells wcrc trapped on a glass filter and dried, and the radioactivity of 
the cells was counted by a liquid scintillation counter. 
2.4, Otircr 
Idcntificution of the N-terminal amino acid sequence [2] and Ihe 
C-terminal amino acid [3] were dcscribcd clsewhcre, as was the cell- 
adhesion assay [2]. 
3. RESULTS AND DISCUSSION 
The strategy for the construction of the expression 
plasmid is shown in Fig. I. The plasmid pCE102 coded 
for a fusion protein of the cell-binding domain of 
human FN (Pro’23u-Ser’5’5, with 277 amino acids, 
numbered by the system of Kornblihtt et al. [7]) bound 
via Met-Ala with human EGF. E. co/i HI3101 cells cary- 
ing the plasmid pCE102 produced a 3%kDa protein, 
which was detected by SDS-PAGE of the whole-ceil 
lysate and by immunoblotting with use of two mono- 
clonal antibodies as described in Materials and 
Methods. The 35-kDa protein, which we named C- 
EGF, accounted for about 20% of the total cell protein 
by densitometric analysis and was produced as inclu- 
sion bodies. The inclusion bodies were washed exten- 
sively, solubilized with a buffer that contained 6 M urea, 
and then purified by ion-exchange chromatography. 
kBa 1 2 3 
Fig. 2. Purification profile of C-EGF by SDS-PAGE. A portion of ihc 
sample in each puritication step was put on a 15% gel and stained with 
Coomassic brilliant blue, Lane I. whole-ccl1 ysate: lane 2. inclusion 
bodies: lane 3, puriftcd C-EGF. 
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Fig. 3. Cell-adhesive activity of C-EGF. Cell-adhesive activity of C- 
EGF was assayed as described elsewhere [2] and compared with ac- 
tivities of native FN and C-279. Open circles, C-179; closed circles. 
C-EGF; closed squares. FN; open squares, EGF. 
The purification profile of C-EGF is shown in Fig. 2. 
The N-terminal amino acid sequence and the C-ter- 
minal amino acid of the purified protein were identical 
with those predicted. The purified C-EGF was refolded 
as described in Materials and Methods and assayed for 
biological activities. C-EGF had the same amount of 
cell-adhesive activity as an unfused fragment of the cell- 
binding domain, C-279 (Pro”“‘-Met”“, with 279 
amino acids [2]; Fig. 3). The EGF activity of C-EGF 
was also compared with that of recombinant human 
EGF (Wakunaga; Fig. 4). C-EGF was almost the same 
as human EGF in its stimulation of [3H]thymidine 
uptake, suggesting that C-EGF contains the native form 
of EGF. EGF had no cell-adhesive activity, and C-279 
had no EGF activity (Figs. 3 and 4). 
These results indicate that C-EGF had both cell- 
adhesive activity and EGF activity, each of which was 
indistinguishable from that of the corresponding un- 
fused protein. Small biologically active peptides uch as 
growth factors, peptide hormones, or neuropeptides are 
often unstable in host cells when produced directly in 
E. coli; EGF is particularly unstable. Stable and effi- 
cient expression of EGF was obtained by fusion of the 
sequente to the C-terminus of the cell-binding domain 
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Fig. 4. EGF activity of C-EGF. The EGF activity of C-EGF was 
assayed as described in Materialsand Methods and compared with the 
activities OTC-279 and native EGF. Open circles, EGF, closed circles, 
C-EGF; open squares, C-279. 
of FN. This fusion protein would probably be more 
effective in therapeutic uses (including wound healing) 
than native EGF, because the moiety of the cell-binding 
domain could act as an anchor by binding to target cells 
that have FN receptors (integrins). Our expression sys- 
tem should be useful for the construction of other DDS 
for biologically active peptides. 
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